Shares in biopharmaceutical group Cyclerion Therapeutics (CYCN) powered 165% higher in pre-market trading today after it said it was merging with peer Korsana Biosciences to help find a treatment for Alzheimer’s disease.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
New Korsana Ticker
Under the terms of the merger agreement, the pre-merger Cyclerion shareholders are expected to own approximately 1.5% of the combined company and the pre-merger Korsana stockholders are expected to own approximately 98.5%.
Upon completion of the deal, the combined company plans to operate under the name Korsana Biosciences, Inc. and trade on Nasdaq under the ticker symbol “KRSA.” It will aim to advance Korsana’s potential therapeutics to treat neurodegenerative diseases.
Indeed, Korsana’s lead program KRSA-028 is a next-generation shuttled monoclonal antibody aimed at the treatment of Alzheimer’s disease. Around 60 million people suffer from the condition worldwide.
In support of the proposed merger, Korsana said it has secured commitments for an oversubscribed private investment worth $380 million from a syndicate of investors led by Fairmount and Venrock Healthcare Capital Partners, with participation from other firms such as Janus Henderson Investors (JHG), J.P. Morgan (JPM) Life Sciences Private Capital, and Sanofi Ventures (SNY).
This will help fund Korsana’s operations into 2029 including the advancement of KRSA-028 through Phase 1 healthy volunteer data expected in mid-2027 and interim proof of concept data in Alzheimer’s patients expected by the end of 2027.
Why the Deal Was Made
“Korsana is determined to deliver breakthrough medicines for patients suffering from neurodegenerative disorders,” said Jonathan Violin, Ph.D., Korsana’s President and Chief Executive Officer. “Patients deserve better options than what is currently available, and we believe our lead program KRSA-028 can deliver a best-in-class product to treat Alzheimer’s disease. We are also building a broader pipeline leveraging our proprietary platform to target other devastating neurodegenerative disorders.”
“Our transaction with Korsana is the result of a comprehensive strategic review, and we believe it represents the best path forward for Cyclerion,” added Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. “Korsana’s promising and innovative pipeline targeting neurodegenerative disorders, beginning with Alzheimer’s disease, provides the potential for significant value creation for Cyclerion’s shareholders.”
The transaction has received approval by the Board of Directors of both companies and is expected to close in the third quarter of 2026.
Is CYCN a Good Stock to Buy Now?
Given the lack of Wall Street analysts covering CYCN, let’s look at how its share price has performed over the last three months. As can be seen below, it is up over 15% during that period.
